Trials / Terminated
TerminatedNCT03212313
Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Tozadenant
A Two-Part, Open-Label, Single-Dose Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Tozadenant
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Biotie Therapies Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
This is a two-part, open label, single-dose study that will evaluate the PK of tozadenant in subjects with different degrees of hepatic impairment to the PK of a single-dose of tozadenant in healthy subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tozadenant | Two 60 mg tablets for a total single study dose of 120 mg |
Timeline
- Start date
- 2017-06-30
- Primary completion
- 2017-12-31
- Completion
- 2017-12-31
- First posted
- 2017-07-11
- Last updated
- 2018-01-04
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03212313. Inclusion in this directory is not an endorsement.